Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The safety and tolerability of regadenoson (REG), a newer adenosine A2a receptor agonist, has not been tested in orthotopic heart transplant (OHT) patients.
Retrospective review of a tertiary care center experience of OHT patients who underwent a REG single-photon emission computed tomography (SPECT) study as part of the work-up for cardiac allograft vasculopathy. The control group included those same patients who had prior adenosine-based SPECT.
A total of 40 patients met the above criteria. Mean time from OHT to adenosine-SPECT and REG-SPECT was 8.2 ± 4.8 years vs 9.8 ± 4.5 years, respectively (P < .001). Both vasodilators had similar side effect profiles (P = .10), produced significant heart rate acceleration and asymptomatic hypotension (P < .001). There were no episodes of bradycardia and/or AV block with REG. Despite adjustment for medication status, adenosine was still associated with more conduction abnormalities (8 vs 1 event with REG, P = .02) including five episodes of 2nd degree AV block (Mobitz type II) and three episodes of sinus pause.
This is the first reported use of REG in OHT patients. REG appears to be safe and well tolerated without significant cardiovascular adverse events.
- Ciliberto, GR, Ruffini, L, Mangiavacchi, M, Parolini, M, Sara, R, Massa, D (2001) Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. Eur Heart J 22: pp. 964-971 CrossRef
- Toft, J, Mortensen, J, Hesse, B (1998) Risk of atrioventricular block during adenosine pharmacologic stress testing in heart transplant recipients. Am J Cardiol 82: pp. 696-697 CrossRef
- Al-Mallah MH, Arida M, Garcia-Sayan E, Assal C, Zegarra GT, Czerska B, et al. Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: A single center experience of 102 transplant patients. Int J Cardiovasc Imaging 2010 [Epub ahead of print].
- Cerqueira, MD, Nguyen, P, Staehr, P, Underwood, SR, Iskandrian, AE (2008) Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 1: pp. 307-316 CrossRef
- Iskandrian, AE, Bateman, TM, Belardinelli, L, Blackburn, B, Cerqueira, MD, Hendel, RC (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14: pp. 645-658 CrossRef
- Henzlova, MJ, Cerqueira, MD, Mahmarian, JJ, Yao, SS (2006) Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol 13: pp. e80-e90 CrossRef
- Thomas, GS, Prill, NV, Majmundar, H, Fabrizi, RR, Thomas, JJ, Hayashida, C (2000) Treadmill exercise during adenosine infusion is safe, results in fewer adverse reactions, and improves myocardial perfusion image quality. J Nucl Cardiol 7: pp. 439-446 CrossRef
- Thomas, GS, Thompson, RC, Miyamoto, MI, Ip, TK, Rice, DL, Milikien, D (2009) The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 16: pp. 63-72 CrossRef
- Ellenbogen, KA, Thames, MD, DiMarco, JP, Sheehan, H, Lerman, BB (1990) Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation 81: pp. 821-828 CrossRef
- Shryock, JC, Belardinelli, L (1997) Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am J Cardiol 79: pp. 2-10 CrossRef
- Dhalla, AK, Wong, MY, Wang, WQ, Biaggioni, I, Belardinelli, L (2006) Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 316: pp. 695-702 CrossRef
- Burki, NK, Lee, LY (2010) Mechanisms of dyspnea. Chest 138: pp. 1196-1201 CrossRef
- Chuaychoo, B, Lee, MG, Kollarik, M, Pullmann, R, Undem, BJ (2006) Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs. J Physiol 575: pp. 481-490 CrossRef
- Lexiscan (regadenoson) injection [package insert]. Deerfield: Astellas Pharma US, Inc; 2008.
- Adenoscan (adenosine) injection [package insert]. Deerfield: Astellas Pharma US, Inc; 2005.
- Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients
Journal of Nuclear Cardiology
Volume 18, Issue 4 , pp 628-633
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- heart transplant
- Industry Sectors
- Author Affiliations
- 1. Heart and Vascular Institute, Henry Ford Hospital, 2799 West Grand Blvd, K-14, Detroit, MI, 48202, USA
- 2. Section of Cardiac Imaging, Heart & Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA